{"product_id":"wat-bcg-matrix","title":"(WAT) Waters Corporation BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVisual. Strategic. Downloadable.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Waters Corporation BCG Matrix helps you see how the company’s products or business units are positioned across Stars, Cash Cows, Question Marks, and Dogs for strategy and capital-allocation decisions. The page already shows a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eXevo tandem MS\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eXevo tandem MS sits in Waters Corporation’s Stars because it serves pharma, biopharma, and regulated testing, where labs pay for sensitivity, selectivity, and speed. Waters reported FY2025 revenue of about $2.96 billion, and mass spectrometry remains a key growth engine. The Xevo line supports premium pricing and strong demand in high-value workflows.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBioAccord LC-MS\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBioAccord LC-MS fits a Star in Waters Corporation's BCG mix because it targets fast-growing biopharma characterization and release testing, where biologics and complex molecules keep expanding. Its value is not just the instrument; it also drives pull-through from software, service, and consumables. That recurring mix supports higher lifetime revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiopharma LC-MS workflows\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBiopharma LC-MS workflows stay a Star for Waters Corporation because drug discovery and development are still core end markets, and labs keep shifting to faster identification and quantification. LC-MS demand is being driven by higher sample loads, tighter turnaround times, and the need to support biologics and complex modalities. Waters is well placed in high-value analytical testing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEnvironmental and food MS\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEnvironmental and food MS stays a strong star for Waters Corporation because PFAS and contaminant testing keep rising, and U.S. EPA set enforceable PFAS limits at 4 ppt for PFOA and PFOS in 2024. Nutrition and food safety labs need LC-MS\/MS methods with lower detection limits, so Waters can keep selling upgrades, columns, and service into the same workflows.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePFAS rules lift sensitivity demand.\u003c\/li\u003e\n\u003cli\u003eFood labs need tighter contaminant checks.\u003c\/li\u003e\n\u003cli\u003eWorkflow upgrades support repeat sales.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eClinical research MS\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eClinical research MS is a strong fit for Waters Corporation because biomarker and protein profiling in trials needs high sensitivity, repeatability, and audit-ready data. Precision medicine keeps demand rising, and regulated labs favor Waters’ validated LC-MS workflows for translational research and clinical use.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBiomarker panels need high MS sensitivity\u003c\/li\u003e\n\u003cli\u003ePrecision medicine supports steady growth\u003c\/li\u003e\n\u003cli\u003eRegulated labs value validated workflows\u003c\/li\u003e\n\u003cli\u003eBest fit: high-growth, strong-position BCG\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWaters’ Growth Engines: Xevo, BioAccord, and PFAS Testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eWaters Corporation’s Stars are Xevo and BioAccord LC-MS plus biopharma, clinical, and PFAS testing workflows: they sit in growing, regulated markets where labs need more sensitivity, speed, and audit-ready data. FY2025 revenue was about $2.96 billion, and these platforms should keep pulling service, software, and consumables.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStar\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003cth\u003eFY2025 anchor\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eXevo \/ BioAccord LC-MS\u003c\/td\u003e\n\u003ctd\u003eHigh-growth pharma and biopharma workflows\u003c\/td\u003e\n\u003ctd\u003e$2.96B Company Name revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePFAS \/ food \/ clinical MS\u003c\/td\u003e\n\u003ctd\u003eRegulated testing, repeat demand\u003c\/td\u003e\n\u003ctd\u003eEPA PFAS limit: 4 ppt\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eWaters Corporation BCG Matrix overview of its portfolio across Stars, Cash Cows, Question Marks, and Dogs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eWaters Corporation BCG Matrix for quick quadrant insight and easier portfolio decisions\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear source trail for Waters Corporation data, making the analysis more credible and easier to validate in investment and strategy decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eACQUITY UPLC systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eACQUITY UPLC systems are a mature installed-base business that still throws off steady cash. Waters Corporation has supported this franchise for over 20 years since the ACQUITY launch in 2004, and replacement and upgrade demand keep revenue recurring. In Waters Corporation's 2025 fiscal year, that kind of stable, high-margin equipment base helped support $2.95 billion in sales and strong operating cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChromatography columns\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eChromatography columns are a classic cash cow for Waters Corporation because they are recurring consumables tied to installed systems and validated methods. In FY2025, Waters Corporation reported net sales of about $2.96 billion, and this repeat-use demand helps support stable, high-margin revenue. Global labs replace columns regularly, so the revenue stream is steady even when instrument sales soften.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSample prep consumables\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSample prep consumables fit Cash Cows because they sell into routine lab workflows and repeat with every run. In Waters Corporation’s FY2025 mix, this kind of recurring consumables demand is far less volatile than new instrument orders, which are more tied to capex cycles. That gives Waters steady revenue from a broad installed base and helps support cash generation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePost-warranty service plans\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eWaters Corporation's post-warranty service plans are a Cash Cow because they sit on a large installed base of analytical systems and keep generating repeat revenue after the original sale. In FY2025, Waters Corporation reported about $2.94 billion in net sales, and service contracts help turn those long-lived placements into steady cash, not just one-time hardware revenue.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRecurring revenue from installed systems\u003c\/li\u003e\n\u003cli\u003eLow volatility versus new equipment sales\u003c\/li\u003e\n\u003cli\u003eSupports cash flow over long lifetimes\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eTA thermal analysis base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTA Instruments is Waters Corporation’s cash cow: it serves mature materials and QC labs, where replacement cycles are slow but switching costs are high. In Waters Corporation’s 2024 base, total sales were about $2.96 billion, and the thermal analysis installed base keeps recurring service, consumables, and upgrades flowing. \u003c\/p\u003e\n\u003cp\u003eThat makes growth slower than mass spectrometry, but cash generation steadier. One line says it best: sticky customers, low drama, reliable cash.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh installed-base retention\u003c\/li\u003e\n\u003cli\u003eRecurring service revenue\u003c\/li\u003e\n\u003cli\u003eSlow growth, steady cash\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWaters’ Installed Base Drives Steady, Recurring Cash\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eWaters Corporation’s cash cows are its installed-base franchises: ACQUITY UPLC, chromatography columns, sample prep, and service plans. These businesses repeat with every run or replacement cycle, so FY2025 cash was steadier than new instrument sales. One line says it best: sticky labs, recurring spend, reliable cash.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCash cow\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eACQUITY UPLC\u003c\/td\u003e\n\u003ctd\u003eLarge installed base\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eColumns\u003c\/td\u003e\n\u003ctd\u003eRecurring consumables\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eService plans\u003c\/td\u003e\n\u003ctd\u003ePost-warranty revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eWaters Corporation Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe Waters Corporation BCG Matrix preview on this page is the exact same document you’ll receive after purchase. No demo content or watered-down version—just the complete, professionally formatted file. Once bought, it’s ready for immediate download, review, and use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy HPLC platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegacy HPLC platforms sit in Waters Corporation's Dogs bucket: older systems replace slowly, face tough price competition, and carry lower margins than newer LC-MS lines. One sentence says it all: they are still needed, but they are no longer the growth engine. With capital budgets shifting toward higher-value LC-MS workflows, growth stays limited.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEntry-level chromatography hardware\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eWaters Corporation’s entry-level chromatography hardware sits in a Dog spot: basic pumps, detectors, and benchtop systems compete in crowded, price-led markets, while Waters’ edge is stronger in higher-end systems. In fiscal 2025, Waters generated about $2.95 billion in net sales, but lower-tier hardware is harder to defend because rivals can match core specs fast. That leaves weaker pricing power and slower growth versus premium platforms.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow-end thermal analyzers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLow-end thermal analyzers fit the Dogs bucket because they serve a mature, slow-moving market where price cuts matter more than innovation. Waters Corporation’s broader FY2025 base was about $2.95 billion in net sales, so these low-spec units add little growth and can dilute margin when replacement demand is weak. With technology changing slowly, they are usually a harvest-or-hold asset, not a growth driver.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCommodity rheometers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCommodity rheometers fit the Dog bucket because entry-level systems face heavy substitution and price pressure, while Waters’ edge is stronger in premium thermal analysis (TA) tools. In FY2025, Waters delivered about $3.0 billion in net sales, but weaker niches like low-end rheometers still look like low-share, low-growth trades versus its higher-value instrumentation mix.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEntry-level demand is easily swapped.\u003c\/li\u003e\n\u003cli\u003ePrice cuts squeeze margins fast.\u003c\/li\u003e\n\u003cli\u003eWaters is stronger in premium TA.\u003c\/li\u003e\n\u003cli\u003eWeak niches match Dog profile.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNon-core accessory bundles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eWaters Corporation’s non-core accessory bundles fit the Dogs bucket: they are low-ticket, easy to copy, and unlikely to lift share. Waters reported $2.96B in 2024 net sales, but these add-ons do not move the needle like core LC and MS systems.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow price, low moat\u003c\/li\u003e\n\u003cli\u003eWeak share impact\u003c\/li\u003e\n\u003cli\u003eKeep inventory lean\u003c\/li\u003e\n\u003cli\u003eUse as attach items only\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eBest move: trim SKUs, protect margin, and let core platforms drive growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWaters’ Dogs: Slow Growth, Weak Pricing, Harvest Now\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDogs in Waters Corporation are legacy HPLC, entry-level hardware, and low-end thermal\/rheology tools: mature markets, weak pricing power, and little share gain. Waters posted about $2.95B in FY2025 net sales, but these lines stay low-growth and margin-light. Best move: harvest, trim SKUs, and keep capital on LC-MS.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDog item\u003c\/th\u003e\n\u003cth\u003eFY2025 view\u003c\/th\u003e\n\u003cth\u003eAction\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegacy HPLC\u003c\/td\u003e\n\u003ctd\u003eSlow replacement\u003c\/td\u003e\n\u003ctd\u003eHarvest\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEntry-level hardware\u003c\/td\u003e\n\u003ctd\u003ePrice-led\u003c\/td\u003e\n\u003ctd\u003eTrim\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLow-end TA\/rheology\u003c\/td\u003e\n\u003ctd\u003eLow growth\u003c\/td\u003e\n\u003ctd\u003eHold\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ewaters_connect software\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ewaters_connect sits in Question Marks: digital lab workflow software is growing as labs automate data and compliance, but it is still less mature than Waters Corporation's core hardware. Waters' FY2024 sales were $2.96 billion, so even modest software share gains can move the needle. The key test is adoption, not just product launch.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNuGenesis informatics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNuGenesis informatics is a question mark for Waters Corporation because lab data keeps rising, especially in regulated settings, but the software market is crowded and share is still hard to win. Its value depends on fast adoption in pharma, biotech, and quality control labs that need audit-ready records and tighter data flow. If Waters Corporation can speed deployment and prove clear workflow gains, NuGenesis could turn into a stronger growth engine.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePFAS testing workflows\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePFAS testing workflows fit a Question Mark: demand is growing fast, but Waters Corporation’s share is still building. In April 2024, the US EPA set enforceable drinking-water limits for 6 PFAS, including 4.0 ppt for PFOA and PFOS, which is forcing labs to expand LC-MS\/MS testing. Waters has the ACQUITY and Xevo tools, but PFAS is still a developing niche, not a scale leader.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eProteomics and biomarker discovery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eProteomics and biomarker discovery are a strong Question Mark for Waters Corporation: protein analysis is growing fast in precision medicine and translational research, but workflows stay fragmented across sample prep, LC-MS, and data analysis. In FY2025, Waters generated about $2.96 billion in net sales, so it has the scale to push harder, but share gains will depend on execution in a complex market. The prize is big, yet the win is not automatic.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\u003cli\u003eLarge demand, low workflow integration, high execution need.\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBioprocess analytics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBioprocess analytics sits in Waters Corporation’s Question Marks: demand is rising because biologics makers want faster batch release and in-line process checks, but large incumbents and site-specific custom methods still slow adoption. The category is supported by biologics growth, with FDA approvals of 55 novel drugs in 2024 and more than half being biologics, which keeps testing demand high.\u003c\/p\u003e\n\u003cp\u003eWaters can scale here if it turns validated methods into repeatable platforms, but conversion will likely lag until GMP users trust the workflow and payback. One watchpoint: biopharma customers still favor proven systems over new tools, so share gains should track adoption speed, not just market growth.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh growth, low current share.\u003c\/li\u003e\n\u003cli\u003eFaster release drives buying urgency.\u003c\/li\u003e\n\u003cli\u003eIncumbents still control many sites.\u003c\/li\u003e\n\u003cli\u003eWaters wins if adoption accelerates.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWaters’ Growth Bets: High Potential, Low Penetration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eWaters Corporation's Question Marks have high growth potential but low share today: waters_connect, NuGenesis, PFAS testing, proteomics, and bioprocess analytics all need faster adoption to matter. With FY2025 net sales of about $2.96 billion, even small gains can help. The real test is conversion, not launch.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eArea\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePFAS\u003c\/td\u003e\n\u003ctd\u003eFast demand\u003c\/td\u003e\n\u003ctd\u003eEPA limits: 4 ppt PFOA\/PFOS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBio analytics\u003c\/td\u003e\n\u003ctd\u003eRising use\u003c\/td\u003e\n\u003ctd\u003e55 novel drugs FDA 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital tools\u003c\/td\u003e\n\u003ctd\u003eLow share\u003c\/td\u003e\n\u003ctd\u003eFY2025 sales: $2.96B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57191831830793,"sku":"wat-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/wat-bcg-matrix.webp?v=1783678646","url":"https:\/\/dcfanalyst.com\/products\/wat-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}